Interior Dermatology Centre | Kelowna, Canada
Status and phase
Conditions
Treatments
About
The primary objectives of this study are to:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Treatment with a biologic product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1
Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:
Treatment with any of the following medications or therapies within 1 week, prior to Day 1:
Treatment with live virus including live attenuated vaccination 12 weeks prior to day 1 pre-randomization.
Treatment with any meningococcal vaccine within 1 year prior to screening, or treatment with any tetanus-, diphtheria-, or pertussis containing vaccine within 5 years prior to screening
Primary purpose
Allocation
Interventional model
Masking
221 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Amgen Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal